Literature DB >> 18220928

Activity of gamma-secretase on substrates other than APP.

Alberto Lleó1.   

Abstract

Gamma-secretase is an intramembranous protein complex that cleaves many type-I membrane proteins, including the Notch receptor and the beta-amyloid precursor protein (APP). Interest in gamma-secretase comes, in part, from the fact that this multiprotein complex is responsible for the cleavage of APP that generates the amyloid-beta peptide (Abeta), one of the primary components of amyloid plaques in Alzheimer's disease (AD). Over the last years, molecular identification of the complex has shown that gamma-secretase is an aspartyl protease composed of four different members that are essential for the enzymatic activity: presenilin 1, aph1, pen-2 and nicastrin. In recent years, an increasing number of type-I membrane proteins have been shown to be cleaved by gamma-secretase. How the enzyme cleaves such a set of substrates with diverse functions and subcellular localizations is not well understood. In overexpression assays, the gamma-secretase cleavage of some substrates releases intracellular domains with signaling properties. On the other hand, the loose specificity required for intramembrane cleavage has raised the possibility of gamma-secretase as the membrane proteasome. The impact of gamma-secretase on other substrates has clear implications for the development of new therapies for AD, and in particular for the search of gamma-secretase inhibitors or modulators. Interference with the cleavage of some of the gamma-secretase substrates has been shown to be associated with serious adverse effects in animal models. The understanding of the mechanism by which gamma-secretase recognizes and cleaves all these proteins is of great importance to clarify the function of gamma-secretase and its role as a therapeutic target in AD, and possibly in other diseases in which gamma-secretase is involved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18220928     DOI: 10.2174/156802608783334060

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  20 in total

1.  RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer.

Authors:  May Chammaa; Agnes Malysa; Carlos Redondo; Hyejeong Jang; Wei Chen; Gerold Bepler; Rodrigo Fernandez-Valdivia
Journal:  J Cell Physiol       Date:  2018-06-28       Impact factor: 6.384

2.  Initial Optimization of a New Series of γ-Secretase Modulators Derived from a Triterpene Glycoside.

Authors:  Nathan O Fuller; Jed L Hubbs; Wesley F Austin; Steffen P Creaser; Timothy D McKee; Robyn M B Loureiro; Barbara Tate; Weiming Xia; Jeffrey L Ives; Mark A Findeis; Brian S Bronk
Journal:  ACS Med Chem Lett       Date:  2012-08-29       Impact factor: 4.345

3.  CpG and non-CpG Presenilin1 methylation pattern in course of neurodevelopment and neurodegeneration is associated with gene expression in human and murine brain.

Authors:  Noemi Monti; Rosaria A Cavallaro; Andrea Stoccoro; Vincenzina Nicolia; Sigfrido Scarpa; Gabor G Kovacs; Maria Teresa Fiorenza; Marco Lucarelli; Eleonora Aronica; Isidre Ferrer; Fabio Coppedè; Aron M Troen; Andrea Fuso
Journal:  Epigenetics       Date:  2020-02-05       Impact factor: 4.528

4.  CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.

Authors:  B P Imbimbo; B Hutter-Paier; G Villetti; F Facchinetti; V Cenacchi; R Volta; A Lanzillotta; M Pizzi; M Windisch
Journal:  Br J Pharmacol       Date:  2009-03       Impact factor: 8.739

Review 5.  Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.

Authors:  Yulia Nefedova; Dmitry Gabrilovich
Journal:  Drug Resist Updat       Date:  2008-10-31       Impact factor: 18.500

6.  Direct inhibition of the NOTCH transcription factor complex.

Authors:  Raymond E Moellering; Melanie Cornejo; Tina N Davis; Cristina Del Bianco; Jon C Aster; Stephen C Blacklow; Andrew L Kung; D Gary Gilliland; Gregory L Verdine; James E Bradner
Journal:  Nature       Date:  2009-11-12       Impact factor: 49.962

7.  Mutations in amyloid precursor protein affect its interactions with presenilin/gamma-secretase.

Authors:  Lauren Herl; Anne V Thomas; Christina M Lill; Mary Banks; Amy Deng; Phill B Jones; Robert Spoelgen; Bradley T Hyman; Oksana Berezovska
Journal:  Mol Cell Neurosci       Date:  2009-03-09       Impact factor: 4.314

8.  Familial Alzheimer's disease-associated presenilin 1 mutants promote γ-secretase cleavage of STIM1 to impair store-operated Ca2+ entry.

Authors:  Benjamin Chun-Kit Tong; Claire Shuk-Kwan Lee; Wing-Hei Cheng; Kwok-On Lai; J Kevin Foskett; King-Ho Cheung
Journal:  Sci Signal       Date:  2016-09-06       Impact factor: 8.192

9.  Mild cholesterol depletion reduces amyloid-beta production by impairing APP trafficking to the cell surface.

Authors:  Cristina Guardia-Laguarta; Mireia Coma; Marta Pera; Jordi Clarimón; Lidia Sereno; José M Agulló; Laura Molina-Porcel; Eduard Gallardo; Amy Deng; Oksana Berezovska; Bradley T Hyman; Rafael Blesa; Teresa Gómez-Isla; Alberto Lleó
Journal:  J Neurochem       Date:  2009-04-27       Impact factor: 5.372

10.  An NSAID-like compound, FT-9, preferentially inhibits gamma-secretase cleavage of the amyloid precursor protein compared to its effect on amyloid precursor-like protein 1.

Authors:  Carlo Sala Frigerio; Thomas L Kukar; Abdul Fauq; Paul C Engel; Todd E Golde; Dominic M Walsh
Journal:  Biochemistry       Date:  2009-11-24       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.